3 Drugs Under FDA Review With Blockbuster Potential

Being the first drugmaker to develop a therapy attacking a new target in cells can result in blockbuster sales. But other companies can wrestle that market share away from the first-in-class drugs with follow-on drugs going after the same targets if the new drugs can provide better safety, efficacy, or dosing than the current offerings.

Here are three follow-on drugs that have proven their worth in clinical trials and are waiting for FDA approvals before the companies can start the competition with the current standard of care.